Bloomberg and other outlets reported that Abbott Laboratories is in acquisition talks to buy Exact Sciences, the diagnostics company behind Cologuard and newly launched multi‑cancer and monitoring assays. Sources say a transaction could be announced within days; market reaction drove Exact Sciences shares sharply higher during trade. The move would expand Abbott’s diagnostics footprint into colorectal and multi‑cancer early detection and could accelerate distributed kit development in oncology testing.